News

arGEN-X raises mio 27.5 Euro in an oversubscribed series B financing round

Date: 01/12/2011

Rotterdam, The Netherlands – arGEN-X announced today that it has closed an oversubscribed series B financing round of 27.5 mio Euro (37 mio USD). The funds will be used to progress differentiated therapeutic antibody programs into clinical development. For further information please be referred to the press release.